STEPS

New Drug Reviews

Sarecycline (Seysara) for the Treatment of Acne

Jedda Rupert, MD, and Pamela Hughes, MD, Nellis Air Force

Base Family Medicine Residency, Las Vegas, Nevada

Sarecycline (Seysara) is a tetracycline-class medication. It is labeled for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris in patients nine years and older.¹

Safety

As with other drugs in the tetracycline class, sarecycline can cause teratogenic effects. Limited human data demonstrate an association between tetracycline use and subsequent birth defects or miscarriage. Tetracyclines are known to cross the placenta into fetal tissues. Animal studies have shown skeletal defects in offspring. Due to the risk of fetal harm, sarecycline should not be used by pregnant women. Patients suspected of being pregnant should immediately discontinue treatment.1 Sarecycline should not be taken by breastfeeding women because of the risk of adverse effects on infant bone and tooth development. In animal studies, sarecycline decreases spermatogenesis at high doses, and decreased fertility may occur in men taking sarecycline.

Like other antibiotics, sarecycline can cause *Clostridioides difficile*—associated diarrhea.¹ Sarecycline should not be administered with oral retinoids because the combination may increase intracranial pressure. Antacids may decrease absorption and should be taken on a separate dosing schedule. Sarecycline can interfere with the bactericidal action of penicillin and should not be administered concurrently. Sarecycline

STEPS new drug reviews cover Safety, Tolerability, Effectiveness, Price, and Simplicity. Each independent review is provided by authors who have no financial association with the drug manufacturer.

This series is coordinated by Allen F. Shaughnessy, PharmD, MMedEd, assistant medical editor.

A collection of STEPS published in *AFP* is available at https://www.aafp.org/afp/steps.

Author disclosure: No relevant financial affiliations.

Drug	Dosage	Dose form	Cost*
Sarecycline (Seysara)	Once daily; recommended dosing is based on patient's body weight	Tablets: 60 mg, 100 mg, 150 mg	\$740

*—Estimated lowest GoodRx price for one month of treatment. Actual cost will vary with insurance and by region. Information obtained at https://www.goodrx.com (accessed June 29, 2020; zip code: 66211).

may decrease plasma prothrombin activity, and decreased anticoagulant dosing may be required due to an increased risk of bleeding. Sarecycline has not demonstrated any clinically significant effects on oral contraceptives containing ethinyl estradiol and norethindrone acetate.¹

Tolerability

Sarecycline is generally well-tolerated.² In clinical trials, the most common adverse effect is nausea, which occurred in about 3% of patients vs. about 2% of those taking placebo.¹ As with other tetracyclines, sarecycline may cause an increased risk of sunburn, and during treatment patients should minimize exposure to sunlight or tanning beds and optimize sun protection measures. Sarecycline may cause lightheadedness, vertigo, and dizziness. Esophageal irritation and ulceration may occur if sarecycline is not swallowed completely. Patients should be instructed to take the medication with a full glass of water.

Effectiveness

Sarecycline has been studied in two 12-week multicenter, randomized, double-blind, placebo-controlled trials of 2,002 patients with moderate to severe acne, an average of 30 inflammatory lesions, and an Investigator's Global Assessment of severity of 3.1 out of a possible 4.0. After 12 weeks of treatment, patients taking sarecycline



Get your clinical updates on the go.

Listen to family physicians and residents discuss key evidence-based learning points from the latest issue of *American Family Physician (AFP)*.

aafp.org/afp/podcast





STEPS

had about 15 fewer lesions compared with 10 fewer lesions in those taking placebo (P < .0001). Approximately one in five patients (21.9% to 22.6%) will have treatment success, defined as at least a two-point drop in the Investigator's Global Assessment and a designation of either "clear" or "almost clear" skin vs. approximately one in 10 patients (10.5% to 15.3%) taking placebo. Patient satisfaction was not assessed in either study. These results are similar to those seen with oral doxycycline and minocycline (Minocin).³

In these studies, sarecycline was used alone without concurrent topical therapy, and it has not been studied in combination with other treatments. Sarecycline has also not been studied in patients with mild to moderate acne or in those with nodular acne. It has not been compared directly with other tetracyclines.

Price

A one-month supply of sarecycline costs approximately \$740. It is significantly more expensive than other tetracyclines commonly used for acne, including doxycycline and minocycline, which cost about \$20 for a 30-day supply. It is not covered by Medicare part D and may not be covered by all insurance plans.

Simplicity

Sarecycline is taken once daily with or without food. The recommended starting dose is determined by body weight (60 mg for persons weighing 33 to 54 kg [73 to 120 lb], 100 mg for those 55 to 84 kg [121 to 186 lb], and 150 mg for those 85 to 136 kg [187 to 300 lb]).

Bottom Line

Sarecycline is a once-daily oral medication for patients with moderate to severe non-nodular acne. Its benefit over less expensive options has not been demonstrated. Due to its high cost, sarecycline should be reserved for patients who have not responded to other conventional treatments for moderate to severe non-nodular acne.

The authors assume full responsibility for the ideas and opinions expressed in this article, which should not be considered the opinions of the U.S. Air Force or the Department of Defense.

Address correspondence to Jedda Rupert, MD, at jedda.p.rupert. mil@mail.mil. Reprints are not available from the authors.

References

- DailyMed. Drug label information. Seysara—sarecycline hydrochloride tablet, coated. Accessed November 16, 2019. https://dailymed.nlm.nih. gov/dailymed/drugInfo.cfm?setid=b200957c-3004-4988-be97-9fd619 a83649
- 2. Leyden JJ, Sniukiene V, Berk DR, et al. Efficacy and safety of sarecycline, a novel, once-daily, narrow spectrum antibiotic for the treatment of moderate to severe facial acne vulgaris: results of a phase 2, doseranging study. *J Drugs Dermatol*. 2018;17(3):333-338.
- 3. Moore A, Green LJ, Bruce S, et al. Once-daily oral sarecycline 1.5 mg/kg/day is effective for moderate to severe acne vulgaris: results from two identically designed, phase 3, randomized, double-blind clinical trials. *J Drugs Dermatol*. 2018;17(9):987-996.■